The objectives of the Northern California Comprehensive Sickle Cell Center (NCCSCC) are:1) to facilitate hemoglobinopathy research in the areas of basic research, clinical science, psychosocial aspects of the disease; and to initiate multicenter collaborative research projects 2) to provide hemoglobinopathy detection, counseling, education and care to affected populations. To pursue these objectives, we have developed interdependent basic research programs at Childrens' Hospital Oakland Research Institute (CHORI) and University of California at San Francisco (UCSF). These basic programs are complemented by core clinical research programs in the West Bay (UCSF/San Francisco General Hospital) and in the East Bay (Childrens' Hospital Oakland]. These programs provide hemoglobinopathy detection, counseling, education and comprehensive care needed to maintain a stable, well characterized group of over 700 patients with sickle cell disease (SCD) who participate in NCCSCC research projects. Clinical, basic and collaborative network research projects aims are: A) To initiate a phase lla, randomized, trial to determine if LY315920 [anti PLA 2 inhibitor] can be safely used to prevent impending ACS and to characterize the mechanisms by which it prevents damage. B) To determine the extent of neurocognitve and neuromimaging abnormalities in neurologically asymtomatic adult SCD patients. C) To understand the mechanisms that result in phospholipid asymmetry in red cell membranes and to determine their in vivo significance in SCD patients by studying physiological processes. D) To construct sickle cell mice utilizing BAC's to isolate the beta-globin clusters from patients with the four sickle haplotypes: Benin, CAR, Senegal and Saudi Arabia, and to study their pathophysiology and rheology. E) Our network project's aim is to test hypothesis that a non-myeloablative conditioning regimen in young adults with symptomatic SCD a can induce stable donor host hematopoietic chimerism after stem cell transplantation from HLA identical sibling donors.
| Milton, Jacqueline N; Gordeuk, Victor R; Taylor 6th, James G et al. (2014) Prediction of fetal hemoglobin in sickle cell anemia using an ensemble of genetic risk prediction models. Circ Cardiovasc Genet 7:110-5 |
| Nazarov, Igor; Lee, Jae W; Soupene, Eric et al. (2012) Multipotent stromal stem cells from human placenta demonstrate high therapeutic potential. Stem Cells Transl Med 1:359-72 |
| Chen, Qiuying; Fabry, Mary E; Rybicki, Anne C et al. (2012) A transgenic mouse model expressing exclusively human hemoglobin E: indications of a mild oxidative stress. Blood Cells Mol Dis 48:91-101 |
| Mansour, Karim M; Kuypers, Frans A; Wang, Tammy N et al. (2011) Secretory phospholipase A2: a marker of infection in febrile children presenting to a pediatric ED. Am J Emerg Med 29:1163-8 |
| Vichinsky, Elliott P; Neumayr, Lynne D; Gold, Jeffrey I et al. (2010) Neuropsychological dysfunction and neuroimaging abnormalities in neurologically intact adults with sickle cell anemia. JAMA 303:1823-31 |
| Soupene, Eric; Dinh, Nghi Phuong; Siliakus, Melvin et al. (2010) Activity of the acyl-CoA synthetase ACSL6 isoforms: role of the fatty acid Gate-domains. BMC Biochem 11:18 |
| Serikov, Vladimir; Hounshell, Catherine; Larkin, Sandra et al. (2009) Human term placenta as a source of hematopoietic cells. Exp Biol Med (Maywood) 234:813-23 |
| Morris, Claudia R; Suh, Jung H; Hagar, Ward et al. (2008) Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 111:402-10 |
| Soupene, Eric; Kuypers, Frans A (2008) Mammalian long-chain acyl-CoA synthetases. Exp Biol Med (Maywood) 233:507-21 |
| Singer, Sylvia T; Vichinsky, Elliott P; Larkin, Sandra et al. (2008) Hydroxycarbamide-induced changes in E/beta thalassemia red blood cells. Am J Hematol 83:842-5 |
Showing the most recent 10 out of 27 publications
